Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

BACKGROUND: The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: He, Xiran, Du, Yang, Wang, Zhijie, Wang, Xin, Duan, Jianchun, Wan, Rui, Xu, Jiachen, Zhang, Pei, Wang, Di, Tian, Yanhua, Han, Jiefei, Fei, Kailun, Bai, Hua, Tian, Jie, Wang, Jie
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594539/
https://ncbi.nlm.nih.gov/pubmed/33115941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000807
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados